What is Allurion Technologies, Inc.?
focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally.
ALUR · Verdict
Moderate reward · elevated risk
ALUR stands out on valuation and volatility, but watch the cash flow signal.
Based on 88% data coverage
ALUR · Verdict
P/E 0.8×
Above average
-190% free-cash-flow margin
Rev -38.1% CAGR · earnings -8.7%
-189% net margin · 0% ROE
Model-based scoring. For information only — not financial advice.
focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 11.10M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.